Long term combination treatment for severe idiopathic pulmonary arterial hypertension 被引量：1

Long term combination treatment for severe idiopathic pulmonary arterial hypertension

下载PDF

导出

摘要 We report the long-term follow-up of 3 cases of severe idiopathic pulmonary arterial hypertension,in whom tadalafil plus sitaxentan combination therapy improved the clinical condition and exercise performance without any relevant adverse event. We report the long-term follow-up of 3 cases of severe idiopathic pulmonary arterial hypertension, in whom tadalafil plus sitaxentan combination therapy improved the clinical condition and exercise performance without any relevant adverse event.

作者 Flora Affuso Plinio Cirillo Antonio Ruvolo Guido Carlomagno Serafino Fazio

机构地区 Department of Internal Medicine

出处《World Journal of Cardiology》 CAS 2010年第3期68-70,共3页 世界心脏病学杂志（英文版）（电子版）

关键词 PULMONARY HYPERTENSION TADALAFIL Sitaxentan ENDOTHELIN RECEPTORS Pulmonary hypertension Tadalafil Sitaxentan Endothelin receptors

分类号 R543.2 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1McLaughlin VV,Badesch DB,Delcroix M,Fleming TR,Gaine SP,Galiè N,Gibbs JS,Kim NH,Oudiz RJ,Peacock A,Provencher S,Sitbon O,Tapson VF,Seeger W.End points and clinical trial design in pulmonary arterial hypertension. Journal of the American College of Cardiology . 2009 被引量：1
2Thenappan T,Shah SJ,Rich S,Tian L,Archer SL,GombergMaitland M.Contemporary survival in patients with pulmonary arterial hypertension: a Reappraisal of the National Institutes of Health Risk Stratification Equation. European Respiratory Journal . 2009 被引量：1
3Galiè N,Brundage BH,Ghofrani HA,Oudiz RJ,Simonneau G,Safdar Z,Shapiro S,White RJ,Chan M,Beardsworth A,Frumkin L,Barst RJ.Tadalafil therapy for pulmonary arterial hypertension. Circulation . 2009 被引量：2
4Barst RJ,Langleben D,Badesch D,Frost A,Lawrence EC,Shapiro S,Naeije R,Galie N.Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology . 2006 被引量：1
5Galiè N,Hoeper MM,Humbert M,Torbicki A,Vachiery JL,Barbera JA,Beghetti M,Corris P,Gaine S,Gibbs JS,Gomez-Sanchez MA,Jondeau G,Klepetko W,Opitz C,Peacock A,Rubin L,Zellweger M,Simonneau G,Vahanian A,Auricchio A,Bax J,Ceconi C,Dean V,Filippatos G,FunckBren.Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Internat. European Heart Journal . 2009 被引量：1
6S.Faruqi,H.Fathi,A.H.Morice.Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. International Journal of Cardiology . 2009 被引量：1
7D’Alonzo GE,Barst RJ,Ayres SM,et al.Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Annals of Internal Medicine . 1991 被引量：1
8R.E. Wrishko,J. Dingemanse,A. Yu,C. Darstein,D.L. Phillips,M.I. Mitchell.Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. Journal of Clinical Pharmacology . 2008 被引量：1
9F Affuso,EA Palmieri,P Conza,V Guardasole,S Fazio.Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. International Journal of Cardiology . 2006 被引量：1